Use of non-subtype B gag proteins for lentiviral packaging

Patent metadata

Field	Value
Publication number	US-9752160-B2
Application number	US-201214346961-A
Country	US
Kind code	B2
Filing date	Sep 25, 2012
Priority date	Sep 26, 2011
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.

First claim

We claim:

1. A lentiviral packaging vector to generate a replication defective lentiviral vector particle, the vector lacking a site and encoding the Gag-Pol protein of HIV-1 NDK, wherein the Gag-Pol protein comprises the amino acid sequence of SEQ ID NO:2 wherein the coding sequence of the Gag-Pol protein is operably linked to an expression control sequence.

2. The vector of claim 1 , wherein the vector is a plasmid comprising a Cytomegalovirus promoter.

3. A cell comprising the vector of claim 1 .

4. The cell of claim 3 , wherein the vector is an integrative vector.

5. A method for generating the packaging vector of claim 1 , the method comprising inserting the nucleotide sequence encoding the Gag-Pol protein of HIV-1 NDK into a plasmid under the control of a non-HIV promoter to generate the packaging vector.

6. A method for generating a lentiviral vector particle, the method comprising administering the packaging vector of claim 1 to a cell with a lentiviral vector comprising 5′ and 3′ lentiviral long terminal repeats and a sequence encoding lentiviral envelope.

7. The method of claim 6 , wherein the packaging vector and the lentiviral vector are plasmids.

8. The method of claim 6 , wherein the packaging vector is a non-integrative vector.

9. The method of claim 6 , wherein the packaging vector is an integrative vector.

10. A lentiviral vector particle comprising Gag-Pol protein of HIV-1 NDK and VSV Env glycoproteins, wherein the Gag-Pol protein comprises the amino acid sequence of SEQ ID NO:2.

11. The lentiviral vector particle of claim 10 , wherein the lentiviral particle encodes a tumor antigen.

12. The lentiviral vector particle of claim 10 , wherein the lentiviral particle comprises an LTR deleted for U3 and R regions.

13. The lentiviral vector particle of claim 10 , wherein the lentiviral particle does not comprise HIV-1 Env proteins.

Assignees

• Theravectys
• Pasteur Institut

Inventors

• Tran Thi-Lan
• Charneau Pierre
• Bauche Cecile

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title

• A61P31/12

  Antivirals · CPC title

• C12N2800/00

  Nucleic acids vectors · CPC title

• A61P31/18

  for HIV · CPC title